Skip to content
sellModerate cluster of 2

Kenneth Bate sold $8.0M of MDGL

director at MADRIGAL PHARMACEUTICALS, INC.. 16,575 shares at an average of $484.30, traded Nov 5, 2025, filed Nov 7, 2025.

Warning score
53
Value
$8.0M
16,575 shares
Holdings after
2,627
-86% from before
From 52-week low
+78%
low $267.56, close $475.87
From 52-week high
0%
high $475.87, as of Nov 5, 2025

Score components

  • Role
    Director
    +15
  • Trade size
    $8.0M at market
    +25
  • Share of holdings sold
    Sold 86% of holdings
    +20
  • Cluster
    2 insiders selling within 14 days
    +8
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

MDGLOct 9, 2026 · close 471.75
Since filing Nov 7, 2025: -3.6%SPY +17.3% · excess -20.9%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001628280-25-050668, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Nov 5, 2025MOption exercise
Common Stock
+5,470$9.45$52k8,097Nov 7, 2025
Nov 5, 2025MOption exercise
Common Stock
+10,000$303.79$3.0M18,097Nov 7, 2025
Nov 5, 2025MOption exercise
Common Stock
+1,105$280.04$309k19,202Nov 7, 2025
Nov 5, 2025SOpen-market sale
Common Stock
-1,763$480.24$847k17,439Nov 7, 2025
Nov 5, 2025SOpen-market sale
Common Stock
-3,259$481.13$1.6M14,180Nov 7, 2025
Nov 5, 2025SOpen-market sale
Common Stock
-1,284$482.41$619k12,896Nov 7, 2025
Nov 5, 2025SOpen-market sale
Common Stock
-2,069$483.41$1.0M10,827Nov 7, 2025
Nov 5, 2025SOpen-market sale
Common Stock
-1,931$484.78$936k8,896Nov 7, 2025
Nov 5, 2025SOpen-market sale
Common Stock
-1,008$485.54$489k7,888Nov 7, 2025
Nov 5, 2025SOpen-market sale
Common Stock
-827$486.73$403k7,061Nov 7, 2025
Nov 5, 2025SOpen-market sale
Common Stock
-2,775$487.49$1.4M4,286Nov 7, 2025
Nov 5, 2025SOpen-market sale
Common Stock
-696$489.09$340k3,590Nov 7, 2025
Nov 5, 2025SOpen-market sale
Common Stock
-933$489.95$457k2,657Nov 7, 2025
Nov 5, 2025SOpen-market sale
Common Stock
-30$490.98$15k2,627Nov 7, 2025
Nov 5, 2025MOption exercise
Stock Option (Right to Buy)derivative
-5,470$0.00$00Nov 7, 2025
Nov 5, 2025MOption exercise
Stock Option (Right to Buy)derivative
-10,000$0.00$00Nov 7, 2025
Nov 5, 2025MOption exercise
Stock Option (Right to Buy)derivative
-1,105$0.00$00Nov 7, 2025

Related signals

Other insiders at MADRIGAL PHARMACEUTICALS, INC. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
30Weak
MDGLsell10b5-1
MADRIGAL PHARMACEUTICALS, INC.
William John Sibold
President and CEO
$6.2M
11,583 shares
-6%
25Weak
MDGLsell 410b5-1
MADRIGAL PHARMACEUTICALS, INC.
Paul A Friedman
director
$14M
24,800 shares
-12%
20Weak
MDGLsell 410b5-1
MADRIGAL PHARMACEUTICALS, INC.
Rebecca Taub
director
$10M
18,650 shares
-4%
50Moderate
MDGLsell 5
MADRIGAL PHARMACEUTICALS, INC.
William John Sibold
President and CEO
$1.4M
2,400 shares
-2%
37Weak
MDGLsell 510b5-1
MADRIGAL PHARMACEUTICALS, INC.
Mardi Dier
EVP and CFO
$2.4M
4,173 shares
-29%
40Moderate
MDGLsell 410b5-1
MADRIGAL PHARMACEUTICALS, INC.
Carole Huntsman
Chief Commercial Officer
$1.1M
1,958 shares
-16%
30Weak
MDGLsell 310b5-1
MADRIGAL PHARMACEUTICALS, INC.
Richard S Levy
director
$4.4M
8,500 shares
-29%
50Moderate
MDGLsell
MADRIGAL PHARMACEUTICALS, INC.
William John Sibold
President and CEO
$3.2M
7,279 shares
-7%
45Moderate
MDGLsell 510b5-1
MADRIGAL PHARMACEUTICALS, INC.
William John Sibold
President and CEO
$3.0M
7,616 shares
-6%
46Moderate
MDGLbuy
MADRIGAL PHARMACEUTICALS, INC.
Baker Bros. Advisors LP
director
$25M
68,618 shares
+36%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Kenneth Bate sold $8.0M of MDGL | InsiderTell